Ultrasound in practice

Algorithms

Pragmatic algorithms to aid diagnosis

Two algorithms propose when ultrasound evaluation may aid diagnosis in patients at risk of rheumatoid arthritis (RA) or suspected RA and in patients who fulfil the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria.

Algorithm 1

US evaluation in patients at risk of RA or suspected RA

Algorithm 2

US evaluation in patients who fulfil ACR/EULAR criteria
US evaluation in patients at risk of RA or suspected RA

Algorithm 1: Diagnosis
US evaluation in patients at risk of RA or suspected RA

US evaluation in patients who fulfil ACR/EULAR criteria

Algorithm 2: Diagnosis
US evaluation in patients who fulfil ACR/EULAR criteria

Pragmatic algorithms to assess therapeutic response

Algorithms that guide ultrasound evaluation of therapeutic response in RA patients. One algorithm is for assessment of patients starting on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biological disease-modifying antirheumatic drugs (bDMARDs); one algorithm is for assessment of patients with loss of treatment response.

Algorithm 3

US evaluation of therapeutic response in RA patients starting csDMARDs or bDMARDs
US evaluation of therapeutic response in RA patients starting csDMARDs or bDMARDs

Algorithm 3: Therapeutic response
US evaluation of therapeutic response in RA patients starting
csDMARDs or bDMARDs

US evaluation in RA patients with loss of treatment response

Algorithm 4: Loss of response
US evaluation in RA patients with loss of treatment response

Pragmatic algorithm to assess remission

Algorithm showing ultrasound evaluation in assessing remission or low disease activity in rheumatoid arthritis patients.

Algorithm 5

US evaluation in assessing remission or low disease activity in RA patients
Next
US evaluation in assessing remission or low disease activity in RA patients

Algorithm 5: Low disease activity/remission
US evaluation in assessing remission or low disease activity in RA patients

Next

© TUI 2019